Journal
EMERGING MICROBES & INFECTIONS
Volume 9, Issue 1, Pages 900-902Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/22221751.2020.1761267
Keywords
SARS; COVID-19; antibody; cross-neutralization; SARS-CoV-2
Categories
Funding
- Singapore National Research Foundation [NRF-2016NRFNSFC002-013]
- National Medical Research Council of the Ministry of Health Singapore [CCGSFPOR20001, STPRG-FY19-001, COVID19RF-003]
Ask authors/readers for more resources
Despite initial findings indicating that SARS-CoV and SARS-CoV-2 are genetically related belonging to the same virus species and that the two viruses used the same entry receptor, angiotensin-converting enzyme 2 (ACE2), our data demonstrated that there is no detectable cross-neutralization by SARS patient sera against SARS-CoV-2. We also found that there are significant levels of neutralizing antibodies in recovered SARS patients 9-17 years after initial infection. These findings will be of significant use in guiding the development of serologic tests, formulating convalescent plasma therapy strategies, and assessing the longevity of protective immunity for SARS-related coronaviruses in general as well as vaccine efficacy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available